What Researchers Did
This review examined the debate surrounding hyperbaric oxygen therapy (HBO2) for neurological conditions like mild to moderate chronic traumatic brain injury (mTBI) and post-concussion syndrome (PCS), focusing on the problematic use of "air sham" controls in past studies.
What They Found
The authors found that for the past 40 years, the use of biologically active "air sham" controls in hyperbaric oxygen (HBO2) studies for neurological conditions has led to a false acceptance of the null hypothesis. Recent Department of Defense/Veterans Administration (DoD/VA) sponsored trials and preliminary reports from the HOPPS Army trial have helped validate effective controls and demonstrate the effectiveness of HBO2 for mTBI and PCS.
What This Means for Canadian Patients
If hyperbaric oxygen therapy (HBO2) is approved for neurological conditions like mild to moderate chronic traumatic brain injury (mTBI) and post-concussion syndrome (PCS), Canadian patients could gain access to a new treatment option. This could potentially offer a safe and viable recovery treatment in the post-acute phase for those suffering from these conditions.
Canadian Relevance
This study does not have a direct Canadian connection.
Study Limitations
As a review article, this study synthesizes existing literature and does not present new primary data or clinical trial results.